Clinical Research Directory

Inclusion Criteria: * Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time), with reaching the goal of mTICI grade 2b-3 * No functional disability before stroke (mRS 0-1) * Angiography (CTA, MRA or DSA) before endovascular therapy confirmed occlusion of the internal carotid artery and/or the middle cerebral artery M1 to M2 segment, with consistent clinical symptoms. * Informed consent is given by the patient or the legal representative. Exclusion Criteria: * Hemorrhagic transformation with mass effect (PH-2 type parenchymal hematoma) occurs during the operation. * Coma, dilated pupils on one or both sides, dull or absent light reflex is noticed before randomization * Dissection of aorta, common carotid artery, internal carotid artery, subclavian artery, intracranial artery; severe bilateral subclavian artery stenosis; contraindications of radial artery puncture were found before or during surgery. * Shock. * Severe cardiomyopathy with heart failure (EGFR ≤ 30% or NYHA Grade IV), acute myocardial infarction, or unstable angina. * Possible infective endocarditis, infective embolism, or vasculitis. * Participating in other clinical research involving drug or device intervention after endovascular therapy. * Women who plan or are pregnant, or breastfeeding. * Severe liver or kidney disease, malignant tumor with a life expectancy is less than 3 months. * The 90-day follow-up is not expected to be completed.